Skip to main content
Hester Biosciences Ltd logo

Hester Biosciences Ltd — Investor Relations & Filings

Ticker · HESTERBIO ISIN · INE782E01017 LEI · 984500836B9EB1DC4935 BSE.NS Manufacturing
Open in API
Filings indexed 672 across all filing types
Latest filing 2019-07-31 Regulatory Filings
Country IN India
Listing BSE.NS HESTERBIO

About Hester Biosciences Ltd

https://www.hester.in/

Hester Biosciences Ltd specializes in the development, manufacturing, and marketing of animal healthcare products. The company primarily focuses on two segments: poultry healthcare and livestock healthcare. Its extensive product portfolio includes a wide range of live and inactivated vaccines, as well as health products such as therapeutics, herbal supplements, and disinfectants. Hester is recognized for its significant contributions to global animal disease control programs, particularly in the eradication of Peste des Petits Ruminants (PPR) and Brucellosis. The company operates advanced manufacturing facilities and maintains a robust distribution network to serve domestic and international markets. By leveraging research and development, Hester provides diagnostic services and technical support to enhance animal productivity and welfare. Its commitment to quality and innovation has established it as a key provider of biologicals and health solutions for the veterinary sector.

Recent filings

Filing Released Lang Actions
Financial Result Updates
Regulatory Filings
2019-07-31 English
Press Release
Earnings Release Classification · 95% confidence The document is a press release dated 31 July 2019 presenting the Q1FY20 financial results of the company. It includes key financial highlights such as net sales, net profit, EPS, and revenue growth by division for the quarter. The document also contains a business overview and profitability analysis for the quarter. The content is focused on quarterly financial performance and does not represent a full annual report or an audit report. It is not a transcript, governance, or legal document. The length is 3790 characters, which is typical for an earnings release press release. Therefore, the document is best classified as an Earnings Release (ER). Q1 2020
2019-07-31 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement of the Board Meeting outcome including the approval and submission of standalone and consolidated unaudited financial results for the quarter ended 30 June 2019. It contains actual financial data such as revenue, expenses, profit before tax, tax expense, and segment results for the quarter. The presence of unaudited quarterly financial results with substantive financial data and analysis indicates this is an Interim / Quarterly Report. The document also mentions the resignation of the CFO, but the primary content is the quarterly financial results. Therefore, the appropriate classification is Interim / Quarterly Report (IR). The document length is 15,000 characters, which supports it being a full report rather than a brief announcement or certification. Q1 2020
2019-07-31 English
Resignation
Board/Management Information Classification · 100% confidence The document is a formal notification addressed to stock exchanges about the resignation of the Chief Financial Officer, a key managerial personnel. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events including changes in management. The content is an announcement of a management change rather than a report or financial statement. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and does not contain financial data or detailed reports, confirming it is not an annual or interim report or any other financial filing.
2019-07-26 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 85% confidence The document is a notification addressed to stock exchanges about an upcoming earnings conference call scheduled for 31 July 2019 to discuss the company's unaudited financial results for the quarter ended 30 June 2019. It includes details about the call timing, participants, and dial-in numbers. The document does not contain actual financial statements or detailed financial analysis but is an announcement of the earnings call event. Therefore, it is classified as a Call Transcript (CT) type document, specifically an announcement of the earnings conference call rather than the transcript itself. Given the content and purpose, the best fitting category is Call Transcript (CT) with moderate to high confidence.
2019-07-24 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a short notice dated 18 July 2019 addressed to stock exchanges informing about a forthcoming Board Meeting scheduled for 31 July 2019. The purpose of the meeting is to consider the unaudited financial results for the quarter ended 30 June 2019. The document is an intimation of a board meeting rather than the financial results themselves or a detailed report. It is a regulatory announcement about a meeting, not a report or transcript. Given the content and length (1033 characters), it fits best under Regulatory Filings (RNS) as a general regulatory announcement and does not qualify as an Interim Report (IR) or Earnings Release (ER) since it does not contain financial data or results, only a meeting notice.
2019-07-18 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.